Skip to content
Evigrade
CriticalClass III antiarrhythmic, selective IKr blocker×Prokinetic, peripheral dopamine D2 receptor antagonist

Updated · Methodology

Mechanism

Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is a class III antiarrhythmic. It blocks the rapid potassium current IKr in heart cells, and the higher its plasma concentration, the longer the QT interval (dofetilide label, US Food and Drug Administration, FDA). The Spanish domperidone SmPC explains that such combinations raise the risk of QT prolongation through pharmacodynamic or pharmacokinetic interactions, and lists dofetilide among the contraindicated class III antiarrhythmics (domperidone SmPC, AEMPS). The liver metabolises domperidone mainly through CYP3A4 (domperidone SmPC, AEMPS). About 80% of a dofetilide dose leaves the body in urine, CYP3A4 metabolises it only to a small extent, and dofetilide does not inhibit this enzyme (FDA dofetilide label). The documents give no data on how one drug changes the level of the other.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Dofetilide can cause serious ventricular arrhythmias, mainly torsade de pointes, a polymorphic ventricular tachycardia. In trials in supraventricular arrhythmias, it occurred in 0.8% of patients, and more often at higher doses (dofetilide label, US Food and Drug Administration, FDA). With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and epidemiological studies link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).

Management

The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names dofetilide (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is not authorised in Spain. According to its US label, use with other drugs that prolong the QT interval has not been studied and is not recommended (dofetilide label, US Food and Drug Administration, FDA). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (domperidone SmPC, AEMPS). Start dofetilide only in a facility that provides continuous electrocardiogram (ECG) monitoring for at least three days, and calculate creatinine clearance before the first dose. Dofetilide is contraindicated if the QT or corrected QT interval (QTc) is above 440 ms, or above 500 ms in patients with ventricular conduction abnormalities (FDA dofetilide label). Bring potassium into the normal range before starting dofetilide and keep it there throughout treatment (FDA dofetilide label). If dofetilide is stopped so that a potentially interacting drug can be given, wait at least two days before starting that drug (FDA dofetilide label). If domperidone and dofetilide have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dofetilide

Other interactions with Domperidone